At a glance
ClinicalIndex Comparison Record- ✓Aged 18 to 80 years old
- ✓ECOG performance status 0 or 1
- ✓No prior lung cancer surgery
- ✓Confirmed invasive lung adenocarcinoma on intraoperative or postoperative pathology
- ✕CTR outside 0-0.5 range or tumor size not 2-3 cm
- ✕Tumor cannot be completely resected per surgeon assessment
- ✕Diagnosis not lung adenocarcinoma confirmed cytologically or pathologically
- ✕Prior lung cancer surgery
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Segmentectomy for Ground Glass-dominant Invasive Lung Cancer With Size of 2-3cm: a Single-arm, Multi-center, Phase III Trial
In Brief
A Phase 3 clinical trial evaluating Segmentectomy for Segmentectomy and Lung Adenocarcinoma. Currently recruiting, targeting 307 participants across 1 site.
Detailed Summary
This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1012. The goal of this clinical trial is to confirm the theraputic effect of segmentectomy for ground glass-dominant invasive lung cancer with size of 2-3cm. The main questions it aims to answer are: * The 5-year disease-free survival of patients having ground glass-dominant invasive lung cancer with size of 2-3cm; * The post-operative lung function tests after receiving segmentectomy. Participants will receive segmentectomy as the surgical procedure.
Study Details
Timeline
Interventions
The lungs are divided into multiple lobes. A segmentectomy involves the removal of part of one of the lobes of the lung to entirely remove a cancerous tumor. segmentectomy can preserve more normal functional lung tissues.